Clinical trial
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated…
NCT00219388 · Orion Corporation, Orion Pharma, Industry · Completed
Key facts
| NCT number | NCT00219388 |
|---|---|
| Title | Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients. |
| Official title | Efficacy and Safety of Short-term Intravenous Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients Treated With Beta-receptor Blocking Agents. |
| Lead sponsor | Orion Corporation, Orion Pharma, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Drug |
| Interventions | Levosimendan |
| Enrollment | 60 |
| Start date | Nov 1, 2002 |
| Completion | Apr 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 20, 2017 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: